Results
| Placebo | Metoprolol | |||||
|---|---|---|---|---|---|---|
| Variable | Baseline | Follow-up | Baseline | Follow-up | Adjusted difference between treatment arms at follow-up* (95% CI) | p Value† |
| Heart rate at rest—beats/min | 67±12 | 62±18 | 68±12 | 55±17 | −8 (−15 to −2) | 0.02 |
| Systolic blood pressure—mm Hg | 136±16 | 134±19 | 133±18 | 124±17 | −7 (−13 to −1) | 0.01 |
| Diastolic blood pressure—mm Hg | 67±7 | 67±6 | 66±9 | 58±9 | −8 (−11 to −6) | <0.001 |
| LV size and function | ||||||
| LV end diastolic volume (MRI)—mL | 246±57 | 256±51 | 251±69 | 267±87 | 8 (−8 to 25) | 0.32 |
| LV end systolic volume (MRI)—mL | 110±33 | 117±34 | 113±32 | 117±46 | −4 (−14 to 6) | 0.44 |
| LVEF (MRI)—% | 55±8 | 55±7 | 55±7 | 57±7 | 2.7 (0.1 to 5.3) | 0.04 |
| LV stroke volume (MRI)—mL | 137±35 | 139±28 | 137±44 | 151±48 | 12 (0 to 23) | 0.04 |
| Aortic regurgitation fraction (MRI)—% | 32±12 | 37±18 | 35±10 | 36±10 | −4 (−9 to 1) | 0.08 |
| Exercise testing | ||||||
| Peak oxygen consumption—mL/kg/min | 35.2±9.0 | 36.6±9.9 | 35.7±8.6 | 34.9±8.6 | −2.0 (−4.2 to 0.2) | 0.08 |
| Peak work—Watts | 237±63 | 241±62 | 230±63 | 229±62 | −6 (−15 to 3) | 0.17 |
| Peak heart rate at exercise—beats/min | 169±16 | 168±16 | 175±15 | 147±23 | −25 (−33 to −18) | <0.001 |
| Natriuretic peptides | ||||||
| NT-proBNP—pg/mL | 62 (39–136) | 58 (42–131) | 66 (36–138) | 142 (93–314) | 138 (71 to 205)‡ | <0.001 |
| Quality of life | ||||||
| EuroQoL visual analogue scale | 82±11 | 82±16 | 84±9 | 85±7 | 1 (−3 to 6) | 0.70 |
| KCCQ overall clinical summary score | 98 (88–100) | 96 (91–100) | 98 (93–100) | 98 (95–100) | 0.4 (−2.2 to 2.8)† | 0.78 |
Results from the 72 patients (36 assigned to placebo and 36 assigned to metoprolol) in whom MRI data were complete at baseline as well as at follow-up after 6 months.
*The difference between the two treatment arms at follow-up was estimated by analysis of covariance, adjusting for baseline values.
†The p values pertain to the baseline-adjusted differences between the two treatment arms at follow-up.
‡Estimated by bootstrapping with 1000 repetitions.
KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; LVEF, LV ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.